We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
No comments yet, be the first to start the discussion!
Swapan Kumar Nath
I suggest trastuzumab deruxtecan
There was a partial response to docetaxel PH initially ...since the goal of the treatment is palliative in principle ,I suggest re-challenge with weekly paclitaxel- trastuzumab pertuzumab
5 Start with SBRT to liver, then 4, if the patient agrees. I’m speaking as a physician with ER-PR-HER2+ ductal carcinoma with no recurrence of liver mets after 14 years. The word “palliative” is not in my vocabulary. I never comment on forums but feel like I need to weigh in on this one. If even one oncologist reading this considers SBRT in a case such as this, I will be happy.
3 or 4
As a RN with Er Pr neg HER2+ with mets to my liver. SBRT to liver mets after 6 rounds of THP followed by H&P (Cleopatra trial). Did the trick for me! 6 years NED on H&P.
As she had a reoccurrence 3 years out, first line metastatic would be 1 and since oligometastisis SBRT to any residual met.
: as cleopatra trial
: recurrent after 3 years completion of adjuvant therapy
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.